Spots Global Cancer Trial Database for Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Official Title: Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea
Study ID: NCT00872391
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Ophthalmology and the Department of Radiotherapy and Radiobiology, Medical University of Vienna, Vienna, , Austria
Contact Details
Name: Martin Zehetmayer, MD
Affiliation: Department of Ophthalmology, Medical University of Vienna, Austria
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
